Diabetes news and diabetes widget

This month's Ophthalmology, the journal of the American Academy of Ophthalmology, reports on the conclusions from a population-based study of risk factors related to progression or regression of diabetic retinopathy over a 25 year period in people with Type 1 diabetes, and on the associa

JDRF announces the launch of a £600,000 ($1 million) project to help develop a new type of insulin treatment for people with type 1 diabetes. SmartInsulin is the idea of Dr Todd Zion, the CEO of SmartCells, Inc., a biotechnology company based in the USA. The concept is simple - deliver insulin in such a way that it is only released into the blood stream when it is needed.

Metabasis Therapeutics (Nasdaq: MBRX) announced today that an oral presentation summarizing the results from the Company's Phase 2a clinical trial for MB07803 was given at the World Congress on Controversies to Consensus in diabetes, Obesity and Hypertension (CODHy), in Barcelona, Spain. MB07803 is the Company's second-generation fructose-1,6-bisphosphatase (FBPase) inhibitor discovered and developed internally for the treatment of type 2 diabetes.

Using an insulin pump to manage diabetes is more convenient than managing the disease with daily insulin injections. That much, physicians already know. But the pump's impact on the lives of diabetics and their primary caregivers is an important question that hasn't been answered yet, Medical College of Georgia researchers say. "Insulin pump technology is touted to improve flexibility in patients' lives," says Dr.

Sugar is naturally present in the blood in the form of glucose and is stored in the liver or adipose tissue (fat) thanks to the action of insulin. Glucose is stored or directly used to ensure satisfactory function of the heart, brain and so on according to the body's demands.

A PhD student at Sydney's Garvan Institute of Medical Research has uncovered an important piece in the puzzle of how insulin works, a problem that has plagued researchers for more than 50 years. This finding brings us one step closer to explaining exactly how insulin prompts fat and muscle cells to absorb glucose. The novel finding by Freddy Yip was

A study appearing November 5 in the journal Cell Metabolism demonstrates that a synthetic new chemical entity protects against diet-induced obesity, improves glucose tolerance and insulin sensitivity and enhances exercise endurance by enhancing fat utilization in certain target tissues. The new chemical entity was developed by Sirtris, a a GSK company, and the research study was led by EPFL professor Johan Auwerx, MD.

A European and American study on a new synthetic drug found that it protected laboratory mice from diet-induced obesity and its potential consequences like glucose intolerance and insensitivity to insulin by activating an enzyme that promoted fat consumption and exercise endurance, leading to suggestions that it could be an important new weapon in the fight against obesity and diabetes.

Reuters - Intense exercise training can help normalize muscle metabolism in people with type 1 diabetes, which could result in "clinically important health benefits," Australian researchers report.

Title: Hormone Lowers Glucose Levels in MiceCategory: health newscreated: 11/5/2008 2:00:00 amlast Editorial review: 11/5/2008